Overview

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Status:
Unknown status

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

This study aim to evaluate the non-inferiority of sustained virologic response in peginterferon alfa-2a and weight-based ribavirin for 16 weeks compare with standard treatment duration of 24 weeks in patients who achieved rapid virologic response with genotype 2 CHC.

Phase:

Phase 4

Details

Lead Sponsor:

Pusan National University Yangsan Hospital

Collaborators:

Incheon St.Mary's Hospital
Inje University
Pusan National University Hospital
Severance Hospital
Soon Chun Hyang University

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin